Latest News on MRK

Financial News Based On Company


Advertisement
Advertisement

Halozyme Falls to 3-Month Low After German Court Lifts Merck Keytruda SC Ban

https://finance.biggo.com/news/2a110731-8c38-4db6-a9f4-a8979fe6b211
Halozyme Therapeutics shares dropped to a three-month low after a German court overturned an injunction that had blocked Merck from selling subcutaneous Keytruda in Germany, a drug Halozyme claims infringes its MDASE technology. Halozyme plans to file a patent infringement lawsuit seeking permanent relief, though a separate Dutch ruling against Keytruda SC in eight European markets remains in effect. Analyst sentiment has cooled with some downgrades, but the consensus rating remains a Buy with an average price target of $118.63.

Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure

https://www.benzinga.com/trading-ideas/movers/26/11/63448265/halozyme-stock-slides-european-patent-fight-with-merck-spurs-fresh-pressure
Halozyme Therapeutics shares are trading lower after a German court overturned a preliminary injunction that had temporarily halted Merck's Keytruda SC launch in Germany. Halozyme plans to immediately file an infringement lawsuit seeking permanent relief and noted a separate Dutch court decision prohibiting Keytruda SC manufacturing and sales in several European countries. Despite the setback, the stock maintains strong momentum and quality scores, though its valuation is seen as weak.

Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?

https://www.tradingview.com/news/zacks:78d07d93f094b:0-moderna-can-the-vaccine-business-fund-its-next-phase-of-growth/
Moderna reported strong Q3 2026 results and raised its full-year revenue guidance, but concerns emerged after its Analyst Day regarding future spending commitments, particularly in oncology, without clear corresponding multi-year revenue projections. The company aims to diversify beyond COVID-19 vaccines by expanding its respiratory and oncology pipelines, despite facing stiff competition. Moderna's stock has significantly outperformed the industry year-to-date, though it trades at a premium valuation.

Merck & Co Inc Stock (MRK) Moved Down by 3.02% on Nov 19: Key Drivers Unveiled

https://www.tradingkey.com/news/market-movers/262313616-market-movers-mrk-20261119
Merck & Co Inc (MRK) stock fell by 3.02% on November 19, driven by concerns over its pipeline execution, Keytruda patent expiry, and volatility in Gardasil sales, particularly in China. The company also faces broader industry headwinds from regulatory scrutiny on drug pricing. Technical analysis indicates a MACD sell signal and an oversold Williams %R, while fundamental support exists from strong cash flow and dividends, with future performance dependent on clinical milestones and pipeline diversification.

Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug

https://www.biospace.com/fda/regeneron-racks-up-another-first-as-fda-greenlights-generalized-myasthenia-gravis-rna-drug
Regeneron and Alnylam Pharmaceuticals have received FDA approval for Livsayis (cemdisiran), their first siRNA therapy for generalized myasthenia gravis (gMG). This marks Regeneron's second new modality approval this year, following a gene therapy for hearing loss in April. Livsayis offers a "first-in-class" treatment option for gMG, providing best-in-class efficacy with convenient quarterly subcutaneous dosing.
Advertisement

AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics

https://finance.yahoo.com/news/abbvie-disco-ink-2-5bn-153340392.html
AbbVie has partnered with German biotech Disco Pharmaceuticals in a deal potentially worth up to $2.5 billion, focusing on developing bispecific cancer therapies for solid tumors. AbbVie will pay $40 million upfront, with additional milestone payments and royalties, to leverage Disco's DISCOtech platform for designing selective bispecifics like AND-gated antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). This collaboration aims to address unmet needs in solid tumor indications by developing therapies with a wider therapeutic window and reduced off-tumor toxicity.

Moderna Just Dropped 17% in a Week as 2027 Cash Costs Head to $4 Billion. Time to Sell, or Load Up?

https://www.tikr.com/pt/blog/moderna-just-dropped-17-in-a-week-as-2027-cash-costs-head-to-4-billion-time-to-sell-or-load-up
Moderna's stock recently dropped 17% after the company guided towards $4 billion in cash costs for 2027, and up to $4.5 billion annually through 2030, largely for cancer drug development including its melanoma vaccine with Merck. This substantial spending raises concerns as analysts' 2028 revenue estimates for Moderna are currently below these projected costs. The article suggests that at 37x forward sales, the stock might be overvalued given the unfiled product launch and increasing expenditures.

Merck inks cancer research deal with AI drug discovery firm Isomorphic Labs

https://seekingalpha.com/news/4674680-merck-inks-cancer-research-deal-isomorphic-labs?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Merck is partnering with AI drug discovery firm Isomorphic Labs to identify new drug candidates for cancer treatment. This collaboration will utilize Isomorphic Labs' drug design engine and data provided by Merck to accelerate the discovery process.

Merck & Co., Inc. (NYSE:MRK) Stock Bumped Up to "Hold" by Zacks Research

https://www.marketbeat.com/instant-alerts/analyst-merck-co-inc-nyse-mrk-stock-bumped-up-to-hold-by-zacks-research-2026-11-19/
Zacks Research has upgraded Merck & Co., Inc. (NYSE:MRK) from a "strong sell" to a "hold" rating. The pharmaceutical company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Despite an insider sale by EVP Richard Deluca, overall analyst sentiment remains a "Moderate Buy" with an average price target of $155.74.

Merck signs Isomorphic Labs to design small-molecule drugs for a cancer target

https://mlq.ai/news/merck-signs-isomorphic-labs-to-design-small-molecule-drugs-for-a-cancer-target/
Merck has announced a research collaboration with Alphabet-backed Isomorphic Labs to discover small-molecule drug candidates for an unnamed oncology target. Isomorphic will use its IsoDDE engine and Merck's datasets to design molecules, with Merck handling development, manufacturing, and commercialization. Isomorphic will receive an upfront payment, milestones, and royalties, with an option to co-fund for higher royalties, though specific financial details were not disclosed.
Advertisement

Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial

https://www.benzinga.com/markets/biotech/26/11/63422882/immutep-reports-81-1-disease-free-survival-rate-in-soft-tissue-sarcoma-trial
Immutep Limited announced positive Phase 2 data from its EFTISARC-NEO study, showing an 81.1% 12-month disease-free survival rate for its combination regimen in high-risk, resectable soft tissue sarcoma. The trial evaluated eftilagimod alfa with Merck & Co.'s Keytruda and radiotherapy before surgery. Exploratory analyses linked higher post-treatment tumor-infiltrating lymphocytes and greater tissue hyalinization and fibrosis to improved survival outcomes.

Adagene doses first patient in phase 1 trial of ADG138

https://ca.investing.com/news/stock-market-news/adagene-doses-first-patient-in-phase-1-trial-of-adg138-93CH-4969381
Adagene Inc. (NASDAQ:ADAG) has announced that the first patient has been dosed in a phase 1 study for ADG138, a double-masked HER2×CD3 bispecific T-cell engager. The open-label study will assess the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors, with dose escalation starting at 2 mg. Preclinical data for ADG138 showed reduced cytokine release, a longer apparent half-life, and tumor regression in various HER2 tumor models.

Global Self Storage Director Russell E. Burke III Acquires 1,000 Shares at $4.815 Each

https://kalkinemedia.com/us/news/announcements/global-self-storage-director-russell-e-burke-iii-acquires-1000-shares-at-4815-each
Global Self Storage, Inc. (NASDAQ:SELF) Director Russell E. Burke III purchased 1,000 shares of common stock at $4.815 per share on November 17, 2026, as disclosed in a Form 4 filed with the SEC on November 18, 2026. This transaction increased Burke's direct beneficial ownership to 43,750 shares. The acquisition was an open-market purchase, and no derivative security transactions were reported.

MRK (NYSE:MRK) Keytruda Qlex Uptake and Winrevair Growth Lift Merck's Full-Year Forecast

https://kalkinemedia.com/us/stocks/healthcare/mrk-nysemrk-keytruda-qlex-uptake-and-winrevair-growth-lift-mercks-full-year-forecast
Merck (NYSE:MRK) surpassed third-quarter expectations, driven by strong sales of its cancer drug Keytruda, particularly the new subcutaneous Keytruda Qlex, and the lung disease treatment Winrevair. The company subsequently raised its full-year sales and earnings outlook, emphasizing pipeline advancements to mitigate future patent expirations. Merck is focusing on transitioning patients to Keytruda Qlex to extend the franchise's life and actively investing in new acquisitions and research to diversify its revenue streams ahead of Keytruda's patent cliff.

Biopharma Co. Targeting Alzheimer's Disease Process, Not Just Symptoms

https://www.streetwisereports.com/article/2026/11/18/biopharma-co-targeting-alzheimers-disease-process-not-just-symptoms.html
Cognition Therapeutics Inc. (CGTX) is developing an oral drug, zervimesine (CT1812), aimed at protecting brain cell connections from damage associated with Alzheimer's disease by preventing toxic amyloid-beta oligomers from binding to synapses. The company is presenting research on plasma p-tau217 screening in its Phase 2 START Alzheimer's trial, which is expected to yield topline results in H2 2027. Additionally, Cognition Therapeutics plans to initiate a Phase 3 program for dementia with Lewy body psychosis in mid-2027, following positive Phase 2 results.
Advertisement

MSD Wins All 14 U.S. Patent Trials Against Halozyme, Easing Patent Risk for Subcutaneous Keytruda

https://finance.biggo.com/news/5cbc8f34-39d5-40b8-9025-821acf3c2f3d
MSD has won all 14 U.S. patent invalidation challenges against Halozyme Therapeutics regarding its MDASE technology, which converts drugs to subcutaneous formulations. This decision significantly eases patent risk for Keytruda Qlex, MSD's subcutaneous cancer drug utilizing Alteogen's ALT-B4 technology, which recently received FDA approval and generated $830 million in Q3 sales. However, the dispute is not fully resolved as Halozyme may appeal the PTAB decision, and a related patent infringement lawsuit in federal court remains pending.

RCS - Hutchmed China Ltd - China NMPA Approval of SYVIK

https://www.tradingview.com/news/reuters.com,2026-11-19:newsml_RSS8664Da:0-rcs-hutchmed-china-ltd-china-nmpa-approval-of-syvik/
HUTCHMED (China) Limited announced that China's NMPA has simultaneously approved two New Drug Applications for SYVIK® (sovleplenib) for the treatment of adult patients with chronic primary Immune Thrombocytopenia (ITP) and Warm Antibody Autoimmune Hemolytic Anemia (wAIHA). SYVIK® is the first novel Syk inhibitor approved in China, marking HUTCHMED's expansion into immunology beyond oncology. The approvals are supported by positive Phase III ESLIM-01 trial data for ITP and Phase II/III ESLIM-02 trial data for wAIHA, demonstrating significant efficacy and a tolerable safety profile.

Alteogen clears US patent hurdle as Merck wins all 14 challenges vs Halozyme

https://www.kedglobal.com/bio-pharma/newsView/ked202611190007
South Korea's Alteogen Inc. has overcome a significant US patent challenge after its partner Merck & Co. won all 14 legal challenges against Halozyme Therapeutics Inc. This victory is crucial for Alteogen, as its licensing agreement with Merck includes up to $1 billion in milestone payments linked to sales targets.

The Zacks Analyst Blog Highlights Merck, Caterpillar, Union Pacific, Daily Journal and Community Bancorp

https://ca.finance.yahoo.com/news/zacks-analyst-blog-highlights-merck-134800098.html
This Zacks Analyst Blog features research reports on 16 major stocks, including Merck & Co., Inc., Caterpillar Inc., and Union Pacific Corp., as well as micro-cap stocks Daily Journal Corp. and Community Bancorp. The reports provide insights into each company's recent performance, growth drivers, and potential risks, with a focus on their financial health and market position.

AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma

https://seekingalpha.com/news/4674531-abbvie-inks-up-to-254b-bispecific-cancer-drug-deal-with-disco-pharma
AbbVie has announced a collaboration with DISCO Pharmaceuticals, involving an upfront payment and potential milestone payments totaling up to $2.54 billion. This deal aims to develop new bispecific cancer treatments, expanding AbbVie's early-stage pipeline in this therapeutic area.
Advertisement

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

https://live.euronext.com/en/financial-news/abbvie-expands-bispecific-cancer-med-push-25-billion-deal-germanys-disco
AbbVie has entered into an agreement with Germany's Disco Pharmaceuticals, committing up to $2.54 billion to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, along with tiered royalties, for its AND-gated bispecific therapeutics. This early-stage collaboration focuses on developing treatments that target cancer cells only when two specific proteins are present simultaneously, aiming to minimize harm to healthy tissue.

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

https://www.reuters.com/legal/transactional/abbvie-expands-bispecific-cancer-med-push-with-up-25-billion-deal-with-germanys-2026-11-19/
AbbVie has agreed to a deal with Germany's Disco Pharmaceuticals worth up to $2.54 billion to develop next-generation bispecific cancer therapies. This collaboration focuses on "AND-gated" bispecific therapeutics for solid tumors, designed to target cancer cells more precisely by requiring the simultaneous presence of two target proteins. Disco will handle research and discovery, with AbbVie having exclusive licensing rights for further development.

Merck and Isomorphic Labs Enter Strategic Research Collaboration

https://www.quantisnow.com/insight/merck-and-isomorphic-labs-enter-strategic-research-collaboration-6799755
Merck has announced a strategic research collaboration with Isomorphic Labs, focusing on AI-driven drug discovery for an oncology target. Isomorphic Labs will use its AI platform to design small molecule candidates, while Merck will handle development, manufacturing, and commercialization. The financial terms include an upfront payment, milestone payments, and tiered royalties for Isomorphic Labs, though the specific amounts were not disclosed.

Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.

https://www.theglobeandmail.com/investing/markets/stocks/MRK-N/pressreleases/8909526/moderna-s-cancer-vaccine-worked-and-the-stock-plunged-anyway-here-s-what-investors-are-missing/
Moderna's personalized melanoma vaccine, developed with Merck, showed promising Phase 3 results, reducing cancer recurrence or death by 42%. Despite this, Moderna's stock fell due to high market expectations and an early leak of results. Analysts later softened their views, recognizing the vaccine's meaningful improvement and potential beyond melanoma, including in pancreatic cancer, suggesting investors might be overlooking a broader opportunity.

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany’s Disco

https://kfgo.com/2026/11/19/abbvie-expands-bispecific-cancer-med-push-with-up-to-2-5-billion-deal-with-germanys-disco/
AbbVie has agreed to a deal worth up to $2.54 billion with Germany's Disco Pharmaceuticals to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, plus royalties, for its AND-gated bispecific therapeutics. This early-stage partnership aims to create treatments that specifically target cancer cells by requiring two proteins to be present simultaneously, thereby potentially reducing harm to healthy tissue.
Advertisement

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

https://www.globenewswire.com/news-release/2026/11/19/3406250/0/en/immutep-reports-encouraging-disease-free-survival-from-eftisarc-neo-phase-ii-trial-in-soft-tissue-sarcoma.html
Immutep Limited announced encouraging new disease-free survival data from its EFTISARC-NEO Phase II trial for high-risk, resectable soft tissue sarcoma, presented at CTOS 2026. The study, evaluating eftilagimod alfa in combination with KEYTRUDA and radiotherapy, showed an 81.1% 12-month disease-free survival rate, with even higher rates in patients exhibiting strong immune responses. These results support the potential of efti-based combination therapy and provide a rationale for further clinical development in this indication.

Merck Director Thomas H. Glocer to Retire at 2027 Annual Meeting

https://www.tradingview.com/news/tradingview:686a45c157f66:0-merck-director-thomas-h-glocer-to-retire-at-2027-annual-meeting/
Merck (MRK) director Thomas H. Glocer announced his plan to retire from the Board of Directors at the company's 2027 Annual Meeting of Shareholders. His retirement is not due to any disagreement with Merck's operations, policies, or practices, and replacement information has not yet been disclosed. This information is based on an SEC 8-K filing from November 18, 2026.

A warrant for 3,333,000 shares counts toward Bayer entities’ reported stake in Senti Biosciences (SNTI).

https://www.stocktitan.net/sec-filings/SNTI/schedule-13d-a-senti-biosciences-holdings-inc-amended-major-sharehold-7da2ee996b9c.html
Bayer HealthCare LLC, Bayer US Holding LLC, and Priyal Patel have reported a beneficial ownership of 6,142,848 shares, or 6.90%, of Senti Biosciences Holdings, Inc. common stock. This reported stake includes 3,333,000 shares issuable under a warrant that is exercisable in full within 60 days. The filing, an amendment to Schedule 13D, indicates that these entities may seek to influence control, unlike passive holders.

Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?

https://www.tradingview.com/news/zacks:f5de8e3bc094b:0-bristol-myers-vs-merck-which-big-pharma-stock-is-the-better-buy/
This article compares Bristol Myers Squibb (BMY) and Merck & Co. (MRK), two major pharmaceutical companies, to determine which offers a better investment opportunity. While BMY has a higher dividend yield and attractive growth from its "Growth Portfolio," it faces risks from generic competition and high debt. MRK, despite the impending patent expiration of its blockbuster drug Keytruda, shows stronger stock performance, diversified growth drivers, an expanding pipeline, and strategic acquisitions, making it the more compelling choice for investors.

Merck & Co Inc Stock (MRK) Moved Down by 3.35% on Nov 18: Facts Behind the Movement

https://www.tradingkey.com/news/market-movers/262311572-market-movers-mrk-20261118
Merck & Co Inc (MRK) stock declined by 3.35% due to operational challenges, sector rotation, and investor concerns over Keytruda's revenue concentration and impending patent cliff. The company also faces issues with its Gardasil vaccine franchise and risks from an aggressive M&A strategy. Despite a strong balance sheet, market participants are looking for proof of pipeline replacement power and stable organic growth beyond its primary assets.
Advertisement

Pfizer Pays $330 Million Upfront for Starna's In Vivo CAR-T Programs in $2.6 Billion Deal

https://finance.biggo.com/news/da621f80-59ef-40e7-ba51-06eb5c3a432b
Pfizer has agreed to an exclusive licensing deal with Starna Therapeutics, paying $330 million upfront for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. The total deal value could reach $2.63 billion including milestones and royalties, giving Pfizer rights outside Greater China and an option for China rights, as well as access to Starna's technology for oncology and a separate research collaboration. This move places Pfizer in the emerging in vivo cell therapy field, which has seen increased dealmaking from other large drugmakers like Eli Lilly.

Lame, suffocated and dead: The drug supersizing America’s cattle

https://nebraskaexaminer.com/2026/11/18/lame-suffocated-and-dead-the-drug-supersizing-americas-cattle/
Elanco Animal Health's drug Experior, approved by the FDA to reduce ammonia emissions in cattle, is now a major profit driver due to its off-label growth-promoting effects, despite concerns about animal welfare. The drug has been linked to increased lameness, bloat, and deaths in cattle in both studies and real-world feedlots. Critics point to the FDA's approval process and the influence of pharmaceutical companies and academia on the livestock industry, raising questions about drug safety and transparency.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Rapid Micro Biosystems, Inc. (NASDAQ: RPID)

https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-rapid-micro-biosystems-inc-nasdaq-rpid-302944037.html
Monteverde & Associates PC, a class action firm, has launched an investigation into Rapid Micro Biosystems, Inc. (NASDAQ: RPID) concerning its proposed sale to Merck KGaA, Darmstadt, Germany. Rapid Micro shareholders are expected to receive $0.75 in cash per share. The firm encourages shareholders with concerns about the fairness of the deal to contact them for more information.

New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026

https://investors.biogen.com/news-releases/news-release-details/new-three-year-real-world-leqembir-data-presented-ctad-2026
Eisai Co., Ltd. and Biogen Inc. announced new three-year real-world findings from the LEADER study, showing LEQEMBI® reduced the rate of progression to moderate or severe Alzheimer's disease dementia by 76%. The study, which included 560 patients, also reported that over 80% of patients remained stable or improved and that amyloid clearance was observed in 77% of patients at sites with follow-up PET data. Safety findings were consistent with previous real-world experience, and an international meta-analysis of 5,000 patients further supported lower ARIA rates compared to clinical trials.

Merck Pulls Plug On Acquired Drug after Safety Review

https://www.benzinga.com/news/health-care/26/11/63392162/merck-pulls-plug-on-acquired-drug-after-safety-review
Merck & Co. has discontinued the clinical development program for nemtabrutinib (MK-1026), an investigational BTK inhibitor, after an external Data Monitoring Committee suggested the risks outweighed the benefits in the Phase 3 BELLWAVE-011 trial. This decision extends to the broader BELLWAVE program, including other Phase 3 studies. The drug was acquired through a Terns Pharmaceuticals Inc. deal.
Advertisement

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

https://www.tradingview.com/news/zacks:d54a2d82c094b:0-merck-ends-nemtabrutinib-development-what-s-next-for-its-pipeline/
Merck has discontinued the development of nemtabrutinib (MK-1026), an investigational Bruton's tyrosine kinase inhibitor for hematologic malignancies, after a review indicated its potential benefits might not outweigh the risks. Despite this setback, Merck's broader pipeline, particularly in oncology, vaccines, and infectious diseases, remains promising, with several late-stage candidates and an expectation of launching 20 new drugs by 2030. The company anticipates over $70 billion in non-risk-adjusted commercial opportunity from its current pipeline by the mid-2030s, more than double Keytruda's peak sales estimate.

Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity

https://finance.yahoo.com/healthcare/articles/moderna-targets-end-cancer-therapy-131303838.html
Moderna and Merck anticipate filing a U.S. application for their individualized cancer therapy, intismeran, by the end of the year, following positive Phase III melanoma results. Moderna views this therapy as a multibillion-dollar opportunity, estimating 22,000 U.S. patients could be eligible for adjuvant melanoma treatment. The company also expects further trial results for kidney and bladder cancer in the coming years and plans to leverage its strong balance sheet to support oncology development.

Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director

https://www.businesswire.com/news/home/20261118702790/en/Thomas-H.-Glocer-to-Retire-From-Merck-Board-of-Directors-in-May-2027-Douglas-M.-Baker-Jr.-Appointed-Independent-Lead-Director
Merck announced that Thomas H. Glocer will retire from its Board of Directors in May 2027. Douglas M. Baker, Jr., who has been on the board since 2022, will succeed Mr. Glocer as independent lead director, effective January 1, 2027. Merck's chairman and CEO, Rob Davis, expressed gratitude for Glocer's contributions and confidence in Baker's leadership.

Merck's board gets a new lead director in January, while Thomas Glocer plans to retire in May.

https://www.stocktitan.net/news/MRK/thomas-h-glocer-to-retire-from-merck-board-of-directors-in-may-2027-224ugqndkgo3.html
Merck announced that Thomas H. Glocer will retire from its Board of Directors in May 2027. Concurrently, Douglas M. Baker, Jr., who joined the board in 2022, has been appointed as the independent lead director, effective January 1, 2027, succeeding Glocer in this role. This change in leadership aims to continue delivering value to stakeholders with experienced leadership in corporate governance.

Nuvation Bio's David Hung: 90% Response Rate in ROS1 Lung Cancer Backs a China-Sourced Drug Strategy

https://finance.biggo.com/news/b50d19af799a7059
David Hung, CEO of Nuvation Bio, discusses the success of obetrosi, a ROS1 lung cancer drug acquired through AnHeart Therapeutics, which boasts a 90% first-line response rate and a median duration of response exceeding four years. Hung emphasizes the drug's efficacy and tolerability, particularly for a younger patient demographic often presenting with brain metastases. Nuvation Bio plans to expand its pipeline through further acquisitions from Chinese labs and academic centers and is developing obetrosi for adjuvant use.
Advertisement

Vaxcyte at jefferies global healthcare conference: adult vaccine path sharpens

https://www.investing.com/news/transcripts/vaxcyte-at-jefferies-global-healthcare-conference-adult-vaccine-path-sharpens-93CH-5035224
Vaxcyte provided updates on its pneumococcal vaccine franchise at the Jefferies Global Healthcare Conference, highlighting positive Phase III adult study data for VAX-31 which met all endpoints and demonstrated non-inferiority to existing vaccines while offering broader coverage. The company aims for a biologics license application filing in the first half of 2028 and anticipates Phase II infant program data in the first half of 2027. Vaxcyte sees a substantial commercial opportunity in the adult market, which is expected to grow significantly, driven by broader serotype coverage.

Merck ends development of its blood cancer drug nemtabrutinib after a monitoring committee flags benefit-risk concerns

https://mlq.ai/news/merck-ends-development-of-its-blood-cancer-drug-nemtabrutinib-after-a-monitoring-committee-flags-benefit-risk-concerns/
Merck has announced the discontinuation of its blood cancer drug nemtabrutinib's clinical development program after an external data monitoring committee for the Phase 3 BELLWAVE-011 study suggested that the benefits might not outweigh the risks. This decision leads to the halt of all BELLWAVE program studies, including BELLWAVE-008 and BELLWAVE-010. Nemtabrutinib was the lead drug acquired by Merck through its $2.7 billion acquisition of ArQule in 2019.

Olema Oncology Announces Preclinical Data Show Potent Oral KAT6A Degraders Inhibit ER+/HER2- Breast Cancer Growth

https://www.quiverquant.com/news/Olema+Oncology+Announces+Preclinical+Data+Show+Potent+Oral+KAT6A+Degraders+Inhibit+ER%2B%2FHER2-+Breast+Cancer+Growth
Olema Oncology reported promising preclinical data on its selective KAT6A degraders, showing strong antitumor activity and good tolerability in ER+/HER2- breast cancer models. These oral compounds demonstrated potent antiproliferative effects in both ESR1-mutant and wild-type models, leading to significant tumor growth inhibition and regression. The findings suggest KAT6A degradation could be a valuable new therapeutic strategy for breast cancer, complementing Olema's existing KAT6 inhibitor.

Pfizer: Strong Growth Momentum And Attractive Valuation Support A Strong Buy (NYSE:PFE)

https://seekingalpha.com/article/4969404-pfizer-stock-strong-growth-momentum-and-attractive-valuation-support-a-strong-buy
Pfizer is rated a Strong Buy due to its improved gross margin, accelerating growth from launched and acquired products, and raised financial guidance. The company's Q3 revenue exceeded expectations, with a significant increase in new product sales. Despite potential risks from Eliquis pricing and Prevnar share losses, Pfizer's valuation appears attractive given its forward earnings multiple and dividend yield.

FDA approves AstraZeneca's Klygefa, a once-weekly self-injected myasthenia gravis drug

https://mlq.ai/news/fda-approves-astrazenecas-klygefa-a-once-weekly-self-injected-myasthenia-gravis-drug/
The FDA has approved AstraZeneca's Klygefa (gefurulimab) for adults with generalized myasthenia gravis who are anti-AChR antibody positive. This once-weekly, self-administered subcutaneous autoinjector is the first dual-binding nanobody C5 inhibitor approved in the US. The approval was based on the PREVAIL Phase 3 trial, which demonstrated significant improvement in patient-reported daily living scores.
Advertisement

Sellas Life Sciences Shares Slide 10% After $150 Million Stock Sale Announced Following Trial-Driven Rally

https://finance.biggo.com/news/0b28156b-5683-41be-a48e-9c36c1b9466d
Sellas Life Sciences Group Inc. (NASDAQ:SLS) announced a $150 million underwritten public offering of common stock, causing its shares to slide 10% in after-hours trading despite a prior 150% jump due to positive Phase 3 trial results for galinpepimut-S (GPS). The trial met its primary endpoint, showing a 41% reduction in the risk of death for acute myeloid leukemia patients. The company plans to seek an accelerated FDA filing and prepare a Biologics License Application for GPS.

After battle with activist investor, Pacira BioSciences finds $1.7 billion deal gain from pain

https://www.bizjournals.com/sanfrancisco/news/2026/11/17/pain-nonopioid-viatris-pacira-chris-christie.html
Viatris has completed its $1.7 billion acquisition of Pacira BioSciences, a pain drug company. This deal comes after Pacira BioSciences had a battle with an activist investor. Former New Jersey governor Chris Christie had served as one of the company's directors for seven years.

Merck stops trials of blood cancer drug after review of risks

https://www.reuters.com/business/healthcare-pharmaceuticals/merck-stops-trials-blood-cancer-drug-after-risk-assessment-2026-11-17/
Merck has announced it will halt the development of its experimental blood cancer drug, nemtabrutinib, following a review that determined its benefits might not outweigh the associated risks. An independent monitoring committee made this recommendation after reviewing late-stage study results, a finding confirmed by Merck's own data analysis. This decision effectively ends the broader development program for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, including two other late-stage trials.

Is IDEAYA Biosciences (IDYA) Undervalued After Its FDA Backed IDE849 Trial Plan?

https://sg.finance.yahoo.com/news/ideaya-biosciences-idya-undervalued-fda-011214792.html
IDEAYA Biosciences (IDYA) is under scrutiny after outlining an FDA-backed registrational plan for IDE849, its DLL3 targeted antibody drug conjugate. Despite a recent share price decline, Simply Wall St analysts suggest the stock is undervalued by 48% at its current price of $27.41 compared to a fair value of $52.75, based on pipeline progress and future execution risk. The company's success hinges on the execution of multiple registrational programs and managing competitive pressures in DLL3 therapies.

Sickle Cell Drug: Marrow Raises $173 Million Without Releasing Anemia or Selectivity Data

https://www.techtimes.com/articles/330910/20261117/sickle-cell-drug-marrow-raises-173-million-without-releasing-anemia-selectivity-data.htm
Marrow Therapeutics launched with $173 million in Series A and B financing to develop MAR-101, a sickle cell and beta thalassemia drug that targets the fetal hemoglobin repressor BCL11A. The drug, which has not yet been tested in humans, aims to be an alternative to gene therapy but lacks public data on its ability to spare red cells' iron supply and selectively silence BCL11A. Investors include OrbiMed, Scion Life Sciences, and venBio, funding manufacturing efforts for global access.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement